Dataset Information

Integrative Multi-OMICs Identifies Therapeutic Response Biomarkers and Confirms Fidelity of Clinically Annotated, Serially Passaged Patient-Derived Xenografts Established from Primary and Metastatic Pediatric and AYA Solid Tumors.

ABSTRACT: Establishment of clinically annotated, molecularly characterized, patient-derived xenografts (PDXs) from treatment-naïve and pretreated patients provides a platform to test precision genomics-guided therapies. An integrated multi-OMICS pipeline was developed to identify cancer-associated pathways and evaluate stability of molecular signatures in a panel of pediatric and AYA PDXs following serial passaging in mice. Original solid tumor samples and their corresponding PDXs were evaluated by whole-genome sequencing, RNA-seq, immunoblotting, pathway enrichment analyses, and the drug−gene interaction database to identify as well as cross-validate actionable targets in patients with sarcomas or Wilms tumors. While some divergence between original tumor and the respective PDX was evident, majority of alterations were not functionally impactful, and oncogenic pathway activation was maintained following serial passaging. CDK4/6 and BETs were prioritized as biomarkers of therapeutic response in osteosarcoma PDXs with pertinent molecular signatures. Inhibition of CDK4/6 or BETs decreased osteosarcoma PDX growth (two-way ANOVA, p < 0.05) confirming mechanistic involvement in growth. Linking patient treatment history with molecular and efficacy data in PDX will provide a strong rationale for targeted therapy and improve our understanding of which therapy is most beneficial in patients at diagnosis and in those already exposed to therapy.

SUBMITTER: Pandya PH

PROVIDER: S-EPMC9818438 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Integrative Multi-OMICs Identifies Therapeutic Response Biomarkers and Confirms Fidelity of Clinically Annotated, Serially Passaged Patient-Derived Xenografts Established from Primary and Metastatic Pediatric and AYA Solid Tumors.

Pandya Pankita H PH Jannu Asha Jacob AJ Bijangi-Vishehsaraei Khadijeh K Dobrota Erika E Bailey Barbara J BJ Barghi Farinaz F Shannon Harlan E HE Riyahi Niknam N Damayanti Nur P NP Young Courtney C Malko Rada R Justice Ryli R Albright Eric E Sandusky George E GE Wurtz L Daniel LD Collier Christopher D CD Marshall Mark S MS Gallagher Rosa I RI Wulfkuhle Julia D JD Petricoin Emanuel F EF Coy Kathy K Trowbridge Melissa M Sinn Anthony L AL Renbarger Jamie L JL Ferguson Michael J MJ Huang Kun K Zhang Jie J Saadatzadeh M Reza MR Pollok Karen E KE

Cancers 20221230 1

Establishment of clinically annotated, molecularly characterized, patient-derived xenografts (PDXs) from treatment-naïve and pretreated patients provides a platform to test precision genomics-guided therapies. An integrated multi-OMICS pipeline was developed to identify cancer-associated pathways and evaluate stability of molecular signatures in a panel of pediatric and AYA PDXs following serial passaging in mice. Original solid tumor samples and their corresponding PDXs were evaluated by whole- ...[more]

PMID: 36612255

Similar Datasets

Project description:Orthoebolaviruses are non-segmented, negative sense RNA viruses that make up the genus Orthoebolavirus in the family Filoviridae. Sudan virus (SUDV) is a highly pathogenic orthoebolavirus that causes severe disease in humans. In the last 45 years, SUDV has been responsible for several outbreaks in eastern Africa, particularly in Sudan and Uganda, with an average case fatality rate of approximately 50 %. Despite having caused numerous outbreaks, including a recent outbreak in 2022, no licensed therapeutics or prophylactics currently exist for Sudan virus disease. Small animal models like mice, hamsters, and guinea pigs have paved the way for the initial evaluation of filovirus countermeasures; however, since filoviruses are apathogenic in immunocompetent rodents, they must first be adapted through serial passaging. As a result of this process, viruses acquire genomic changes that may contribute to increased virulence and lethality. Currently, only a single immunocompetent small animal model exists for SUDV, where the virus was serially passaged in guinea pigs until uniform lethality was observed. To better understand the serial passaging process, we used next-generation sequencing to identify and quantify the mutations that arose throughout the adaptation process in guinea pigs. We identified 7 nonsynonymous and 9 synonymous mutations that were present at frequencies near 100 % at the end of serial passaging. The glycoprotein and virion protein (VP) 40 harboured many of the substitutions, most of which were nonsynonymous, while VP35 and VP24 each maintained a single nonsynonymous mutation. These results are consistent with the previously determined genome sequence, obtained by Sanger sequencing, with two notable exceptions: we identified a novel mutation in VP40, but we were unable to confirm the mutation in the genome leader, due to poor sequence coverage. This analysis has allowed us to identify adaptive hotspots within the viral genome, which may hint at the molecular determinants contributing to pathogenicity.

Project description:Leukemias are a group of malignancies of the blood and bone marrow. Multiple types of leukemia are known, however reliable treatments have not been developed for most leukemia types. Furthermore, even relatively reliable treatments can result in relapses. MicroRNAs (miRNAs) are a class of short, noncoding RNAs responsible for epigenetic regulation of gene expression and have been proposed as a source of potential novel therapeutic targets for leukemias. In order to identify central miRNAs for leukemia, we conducted data synthesis using two databases: miRTarBase and DISNOR. A total of 137 unique miRNAs associated with 16 types of leukemia were retrieved from miRTarBase and 86 protein-coding genes associated with leukemia were retrieved from the DISNOR database. Based on these data, we formed a visual network of 248 miRNA-target interactions (MTI) between leukemia-associated genes and miRNAs associated with ≥4 leukemia types. We then manually reviewed the literature describing these 248 MTIs for interactions identified in leukemia studies. This manually curated data was then used to visualize a network of 64 MTIs identified in leukemia patients, cell lines and animal models. We also formed a visual network of miRNA-leukemia associations. Finally, we compiled leukemia clinical trials from the ClinicalTrials database. miRNAs with the highest number of MTIs were miR-125b-5p, miR-155-5p, miR-181a-5p and miR-19a-3p, while target genes with the highest number of MTIs were TP53, BCL2, KIT, ATM, RUNX1 and ABL1. The analysis of 248 MTIs revealed a large, highly interconnected network. Additionally, a large MTI subnetwork was present in the network visualized from manually reviewed data. The interconnectedness of the MTI subnetwork suggests that certain miRNAs represent central disease molecules for multiple leukemia types. Additional studies on miRNAs, their target genes and associated biological pathways are required to elucidate the therapeutic potential of miRNAs in leukemia.

Dataset Information

Integrative Multi-OMICs Identifies Therapeutic Response Biomarkers and Confirms Fidelity of Clinically Annotated, Serially Passaged Patient-Derived Xenografts Established from Primary and Metastatic Pediatric and AYA Solid Tumors.

Publications

Integrative Multi-OMICs Identifies Therapeutic Response Biomarkers and Confirms Fidelity of Clinically Annotated, Serially Passaged Patient-Derived Xenografts Established from Primary and Metastatic Pediatric and AYA Solid Tumors.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets